Mecillinam - Utility Therapeutics
Alternative Names: AmdinocillinLatest Information Update: 03 Feb 2023
At a glance
- Originator LEO Pharma
- Developer LEO Pharma; UTILITY therapeutics
- Class Anti-infectives; Antibacterials; Carboxylic acids; Penicillins; Urinary anti-infective agents
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Urinary tract infections
Most Recent Events
- 03 Feb 2023 Phase-I clinical trials in Urinary tract infections (Complicated) in USA (IV) (Utility therapeutics pipeline, February 2022)
- 03 Feb 2023 Phase-I clinical trials in Urinary tract infections (Complicated) in USA (PO) (Utility therapeutics pipeline, February 2022)
- 19 Oct 2022 Pharmacodynamics data from a preclinical trial in Urinary tract infections presented at the IDWeek 2022 (IDW-2022)